Does Arimidex (anastrozole) cause side effects?
Estrogen causes or increases growth of certain breast cancers. Arimidex works by blocking aromatase enzyme, which is involved in estrogen production in the body, which leads to decreased tumor size or delayed progression of tumor growth in some women.
Common side effects of Arimidex include:
- hot flashes,
- increased blood pressure,
- bone pain,
- weakened bones,
- sleeplessness, and
Serious side effects of Arimidex include:
- skin reactions such as lesions, ulcers, or blisters;
- allergic reactions with swelling of the face, lips, tongue, and/or throat that may cause difficulty in swallowing and/or breathing; and
- changes in liver function tests, including inflammation of the liver (symptoms may include malaise, jaundice, liver pain, or liver swelling).
Estrogens decrease the effect of Arimidex by increasing estrogen levels in the body.
Arimidex (anastrozole) side effects list for healthcare professionals
Serious adverse reactions with Arimidex occurring in less than 1 in 10,000 patients, are:
- 1) skin reactions such as lesions, ulcers, or blisters;
- 2) allergic reactions with swelling of the face, lips, tongue, and/or throat. This may cause difficulty in swallowing and/or breathing; and
- 3) changes in blood tests of the liver function, including inflammation of the liver with symptoms that may include a general feeling of not being well, with or without jaundice, liver pain or liver swelling.
Common adverse reactions (occurring with an incidence of ≥ 10%) in women taking Arimidex included:
- hot flashes,
- nausea and vomiting,
- back pain,
- bone pain,
- peripheral edema,
- increased cough,
- pharyngitis and lymphedema.
In the ATAC trial, the most common reported adverse reaction ( > 0.1%) leading to discontinuation of therapy for both treatment groups was hot flashes, although there were fewer patients who discontinued therapy as a result of hot flashes in the Arimidex group.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Clinical Trials Experience
Adverse reaction data for adjuvant therapy are based on the ATAC trial. The median duration of adjuvant treatment for safety evaluation was 59.8 months and 59.6 months for patients receiving Arimidex 1 mg and tamoxifen 20 mg, respectively.
Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment or within 14 days of the end of treatment are presented in Table 1.
Table 1 :Adverse reactions occurring with an incidence of at least 5% in either treatment group during treatment, or within 14 days of the end of treatment in the ATAC trial*
|Body system and adverse reactions by COSTART preferred term*||Arimidex 1 mg|
(N§ = 3092)
|Tamoxifen 20 mg|
(N§ = 3094)
|Body as a whole|
|Asthenia||575 (19)||544 (18)|
|Back pain||321 (10)||309 (10)|
|Headache||314 (10)||249 (8)|
|Abdominal pain||271 (9)||276 (9)|
|Infection||285 (9)||276 (9)|
|Accidental injury||311 (10)||303 (10)|
|Flu syndrome||175 (6)||195 (6)|
|Chest pain||200 (7)||150 (5)|
|Neoplasm||162 (5)||144 (5)|
|Cyst||138 (5)||162 (5)|
|Vasodilatation||1104 (36)||1264 (41)|
|Hypertension||402 (13)||349 (11)|
|Nausea||343 (11)||335 (11)|
|Constipation||249 (8)||252 (8)|
|Diarrhea||265 (9)||216 (7)|
|Dyspepsia||206 (7)||169 (6)|
|Gastrointestinal disorder||210 (7)||158 (5)|
|Hemic and lymphatic|
|Lymphedema||304 (10)||341 (11)|
|Anemia||113 (4)||159 (5)|
|Metabolic and nutritional|
|Peripheral edema||311 (10)||343 (11)|
|Weight gain||285 (9)||274 (9)|
|Hypercholesterolemia||278 (9)||108 (3.5)|
|Arthritis||512 (17)||445 (14)|
|Arthralgia||467 (15)||344 (11)|
|Osteoporosis||325 (11)||226 (7)|
|Bone pain||201 (7)||185 (6)|
|Arthrosis||207 (7)||156 (5)|
|Joint Disorder||184 (6)||160 (5)|
|Myalgia||179 (6)||160 (5)|
|Depression||413 (13)||382 (12)|
|Insomnia||309 (10)||281 (9)|
|Dizziness||236 (8)||234 (8)|
|Anxiety||195 (6)||180 (6)|
|Paresthesia||215 (7)||145 (5)|
|Pharyngitis||443 (14)||422 (14)|
|Cough increased||261 (8)||287 (9)|
|Dyspnea||234 (8)||237 (8)|
|Sinusitis||184 (6)||159 (5)|
|Bronchitis||167 (5)||153 (5)|
|Skin and appendages|
|Rash||333 (11)||387 (13)|
|Sweating||145 (5)||177 (6)|
|Cataract Specified||182 (6)||213 (7)|
|Leukorrhea||86 (3)||286 (9)|
|Urinary tract infection||244 (8)||313(10)|
|Breast pain||251 (8)||169 (6)|
|Breast Neoplasm||164 (5)||139 (5)|
|Vulvovaginitis||194 (6)||150 (5)|
|Vaginal Hemorrhage¶||122 (4)||180 (6)|
|Vaginitis||125 (4)||158 (5)|
|* The combination arm was discontinued due to lack of efficacy benefit at 33 months of follow-up.|
†COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms.
‡ A patient may have had more than 1 adverse reaction, including more than 1 adverse reaction in the same body system.
§ N=Number of patients receiving the treatment.
¶Vaginal Hemorrhage without further diagnosis.
Certain adverse reactions and combinations of adverse reactions were prospectively specified for analysis, based on the known pharmacologic properties and side effect profiles of the two drugs (see Table 2).
Table 2 : Number of Patients with Pre-specified Adverse Reactions in ATAC Trial*
|Hot Flashes||1104 (36)||1264 (41)||0.80||0.73 -0.89|
|Musculoskeletal Events'1||1100 (36)||911 (29)||1.32||1.19 -1.47|
|Fatigue/Asthenia||575 (19)||544 (18)||1.07||0.94 -1.22|
|Mood Disturbances||597 (19)||554 (18)||1.10||0.97 - 1.25|
|Nausea and Vomiting||393 (13)||384 (12)||1.03||0.88 -1.19|
|All Fractures||315 (10)||209 (7)||1.57||1.30 -1.88|
|Fractures of Spine, Hip, or Wrist||133 (4)||91 (3)||1.48||1.13 -1.95|
|Wrist/Colles’ fractures||67 (2)||50 (2)|
|Spine fractures||43 (1)||22 (1)|
|Hip fractures||28 (1)||26 (1)|
|Cataracts||182 (6)||213 (7)||0.85||0.69 -1.04|
|Vaginal Bleeding||167 (5)||317(10)||0.50||0.41 -0.61|
|Ischemic Cardiovascular Disease||127 (4)||104 (3)||1.23||0.95 -1.60|
|Vaginal Discharge||109 (4)||408 (13)||0.24||0.19 -0.30|
|Venous Thromboembolic events||87 (3)||140 (5)||0.61||0.47 -0.80|
|Deep Venous Thromboembolic Events||48 (2)||74 (2)||0.64||0.45 -0.93|
|Ischemic Cerebrovascular Event||62 (2)||88 (3)||0.70||0.50 -0.97|
|Endometrial Cancer*||4 (0.2)||13 (0.6)||0.31||0.10 -0.94|
|* Patients with multiple events in the same category are counted only once in that category.|
†Refers to joint symptoms, including joint disorder, arthritis, arthrosis and arthralgia.
‡ Percentages calculated based upon the numbers of patients with an intact uterus at baseline
Ischemic Cardiovascular Events
Between treatment arms in the overall population of 6186 patients, there was no statistical difference in ischemic cardiovascular events (4% Arimidex vs. 3% tamoxifen).
In the overall population, angina pectoris was reported in 71/3092 (2.3%) patients in the Arimidex arm and 51/3094 (1.6%) patients in the tamoxifen arm; myocardial infarction was reported in 37/3092 (1.2%) patients in the Arimidex arm and 34/3094 (1.1%) patients in the tamoxifen arm.
In women with pre-existing ischemic heart disease 465/6186 (7.5%), the incidence of ischemic cardiovascular events was 17% in patients on Arimidex and 10% in patients on tamoxifen. In this patient population, angina pectoris was reported in 25/216 (11.6%) patients receiving Arimidex and 13/249 (5.2%) patients receiving tamoxifen; myocardial infarction was reported in 2/216 (0.9%) patients receiving Arimidex and 8/249 (3.2%) patients receiving tamoxifen.
Bone Mineral Density Findings
Results from the ATAC trial bone substudy at 12 and 24 months demonstrated that patients receiving Arimidex had a mean decrease in both lumbar spine and total hip bone mineral density (BMD) compared to baseline. Patients receiving tamoxifen had a mean increase in both lumbar spine and total hip BMD compared to baseline.
Because Arimidex lowers circulating estrogen levels it may cause a reduction in bone mineral density.
A post-marketing trial assessed the combined effects of Arimidex and the bisphosphonate risedronate on changes from baseline in BMD and markers of bone resorption and formation in postmenopausal women with hormone receptor-positive early breast cancer. All patients received calcium and vitamin D supplementation. At 12 months, small reductions in lumbar spine bone mineral density were noted in patients not receiving bisphosphonates. Bisphosphonate treatment preserved bone density in most patients at risk of fracture.
Postmenopausal women with early breast cancer scheduled to be treated with Arimidex should have their bone status managed according to treatment guidelines already available for postmenopausal women at similar risk of fragility fracture.
During the ATAC trial, more patients receiving Arimidex were reported to have an elevated serum cholesterol compared to patients receiving tamoxifen (9% versus 3.5%, respectively).
A post-marketing trial also evaluated any potential effects of Arimidex on lipid profile. In the primary analysis population for lipids (Arimidex alone), there was no clinically significant change in LDL-C from baseline to 12 months and HDL-C from baseline to 12 months.
In secondary population for lipids (Arimidex+risedronate), there also was no clinically significant change in LDL-C and HDL-C from baseline to 12 months.
In both populations for lipids, there was no clinically significant difference in total cholesterol (TC) or serum triglycerides (TG) at 12 months compared with baseline.
In this trial, treatment for 12 months with Arimidex alone had a neutral effect on lipid profile. Combination treatment with Arimidex and risedronate also had a neutral effect on lipid profile.
The trial provides evidence that postmenopausal women with early breast cancer scheduled to be treated with Arimidex should be managed using the current National Cholesterol Education Program guidelines for cardiovascular risk-based management of individual patients with LDL elevations.
Other Adverse Reactions
Patients receiving Arimidex had an increase in joint disorders (including arthritis, arthrosis and arthralgia) compared with patients receiving tamoxifen. Patients receiving Arimidex had an increase in the incidence of all fractures (specifically fractures of spine, hip and wrist) [315 (10%)] compared with patients receiving tamoxifen [209 (7%)].
Patients receiving Arimidex had a higher incidence of carpal tunnel syndrome [78 (2.5%)] compared with patients receiving tamoxifen [22 (0.7%)].
Vaginal bleeding occurred more frequently in the tamoxifen-treated patients versus the Arimidex-treated patients 317 (10%) versus 167 (5%), respectively.
Patients receiving Arimidex had a lower incidence of hot flashes, vaginal bleeding, vaginal discharge, endometrial cancer, venous thromboembolic events and ischemic cerebrovascular events compared with patients receiving tamoxifen.
10-Year Median Follow-Up Safety Results From The ATAC Trial
Results are consistent with the previous analyses.
Serious adverse reactions were similar between Arimidex (50%) and tamoxifen (51%).
- Cardiovascular events were consistent with the known safety profiles of Arimidex and tamoxifen.
- The cumulative incidences of all first fractures (both serious and non-serious, occurring either during or after treatment) was higher in the Arimidex group (15%) compared to the tamoxifen group (11%). This increased first fracture rate during treatment did not continue in the post-treatment follow-up period.
- The cumulative incidence of new primary cancers was similar in the Arimidex group (13.7%) compared to the tamoxifen group (13.9%). Consistent with the previous analyses, endometrial cancer was higher in the tamoxifen group (0.8%) compared to the Arimidex group (0.2%).
- The overall number of deaths (during or off-trial treatment) was similar between the treatment groups. There were more deaths related to breast cancer in the tamoxifen than in the Arimidex treatment group.
Adverse reactions occurring with an incidence of at least 5% in either treatment group of trials 0030 and 0027 during or within 2 weeks of the end of treatment are shown in Table 3.
Table 3 : Adverse Reactions Occurring with an Incidence of at Least 5% in Trials 0030 and 0027
|Number (%) of subjects|
|Arimidex (N=506)||Tamoxifen (N=511)|
|Back pain||60(12)||68 (13)|
|Headache||47 (9)||40 (8)|
|Abdominal pain||40 (8)||38 (7)|
|Chest pain||37 (7)||37 (7)|
|Flu syndrome||35 (7)||30 (6)|
|Pelvic pain||23 (5)||30 (6)|
|Vasodilation||128 (25)||106 (21)|
|Hypertension||25 (5)||36 (7)|
|Nausea||94 (19)||106 (21)|
|Constipation||47 (9)||66 (13)|
|Diarrhea||40 (8)||33 (6)|
|Vomiting||38 (8)||36 (7)|
|Anorexia||26 (5)||46 (9)|
|Metabolic and Nutritional|
|Peripheral edema||51 (10)||41 (8)|
|Bone pain||54 (11)||52 (10)|
|Dizziness||30 (6)||22 (4)|
|Insomnia||30 (6)||38 (7)|
|Depression||23 (5)||32 (6)|
|Hypertonia||16 (3)||26 (5)|
|Cough increased||55 (11)||52 (10)|
|Dyspnea||51 (10)||47 (9)|
|Pharyngitis||49 (10)||68 (13)|
|Skin and appendages|
|Rash||38 (8)||34 (8)|
|Leukorrhea||9 (2)||31 (6)|
|* A patient may have had more than 1 adverse event.|
Less frequent adverse experiences reported in patients receiving Arimidex l mg in either Trial 0030 or Trial 0027 were similar to those reported for second-line therapy.
Based on results from second-line therapy and the established safety profile of tamoxifen, the incidences of 9 pre-specified adverse event categories potentially causally related to one or both of the therapies because of their pharmacology were statistically analyzed. No significant differences were seen between treatment groups.
Table 4 : Number of Patients with Pre-specified Adverse Reactions in Trials 0030 and 0027
|Adverse Reaction*||Number (n) and Percentage of Patients|
|Arimidex 1 mg|
|NOLVADEX 20 mg|
|Depression||23 (5)||32 (6)|
|Tumor Flare||15 (3)||18 (4)|
|Thromboembolic Disease†||18 (4)||33 (6)|
|Coronary and Cerebral‡||13||19|
|Gastrointestinal Disturbance||170 (34)||196 (38)|
|Hot Flushes||134 (26)||118 (23)|
|Vaginal Dryness||9 (2)||3 (1)|
|Lethargy||6 (1)||15 (3)|
|Vaginal Bleeding||5 (1)||11 (2)|
|Weight Gain||11 (2)||8 (2)|
|* A patient may have had more than 1 adverse reaction.|
†Includes pulmonary embolus, thrombophlebitis, retinal vein thrombosis.
‡ Includes myocardial infarction, myocardial ischemia, angina pectoris, cerebrovascular accident, cerebral ischemia and cerebral infarct.
Arimidex was tolerated in two controlled clinical trials (i.e., Trials 0004 and 0005), with less than 3.3% of the Arimidex-treated patients and 4.0% of the megestrol acetate-treated patients withdrawing due to an adverse reaction.
The principal adverse reaction more common with Arimidex than megestrol acetate was diarrhea. Adverse reactions reported in greater than 5% of the patients in any of the treatment groups in these two controlled clinical trials, regardless of causality, are presented below:
Table 5 :Number (N) and Percentage of Patients with Adverse Reactions in Trials 0004 and 0005
|Adverse Reaction*||Arimidex 1 mg|
|Arimidex 10 mg|
|Megestrol Acetate 160 mg|
|* A patient may have had more than one adverse reaction. Other less frequent (2% to 5%) adverse reactions reported in patients receiving Arimidex l mg in either Trial 0004 or Trial 0005 are listed below. These adverse experiences are listed by body system and are in order of decreasing frequency within each body system regardless of assessed causality.|
Hepatic: Gamma GT increased; SGOT increased; SGPT increased Hematologic: Anemia; leukopenia
Musculoskeletal: Myalgia; arthralgia; pathological fracture
Skin and Appendages: Hair thinning (alopecia); pruritus
The incidences of the following adverse reaction groups potentially causally related to one or both of the therapies because of their pharmacology, were statistically analyzed:
- weight gain,
- thromboembolic disease,
- gastrointestinal disturbance,
- hot flushes, and
- vaginal dryness.
These six groups, and the adverse reactions captured in the groups, were prospectively defined. The results are shown in the table below.
Table 6 : Number (n) and Percentage of Patients with Pre-specified Adverse Reactions in Trials 0004 and 0005
|Adverse Reaction Group||Arimidex1 mg|
|Megestrol Acetate160 mg|
These adverse reactions are reported voluntarily from a population of uncertain size. Therefore, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The following have been reported in post-approval use of Arimidex:
- Hepatobiliary events including increases in alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-GT, and bilirubin; hepatitis
- Rash including cases of mucocutaneous disorders such as erythema multiforme and Stevens-Johnson syndrome
- Cases of allergic reactions including angioedema, urticaria and anaphylaxis
- Myalgia, trigger finger and hypercalcemia (with or without an increase in parathyroid hormone)
What drugs interact with Arimidex (anastrozole)?
Co-administration of anastrozole and tamoxifen in breast cancer patients reduced anastrozole plasma concentration by 27%. However, the co-administration of anastrozole and tamoxifen did not affect the pharmacokinetics of tamoxifen or N-desmethyltamoxifen.
At a median follow-up of 33 months, the combination of Arimidex and tamoxifen did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation. This treatment arm was discontinued from the trial. Based on clinical and pharmacokinetic results from the ATAC trial, tamoxifen should not be administered with anastrozole.
Estrogen-containing therapies should not be used with Arimidex as they may diminish its pharmacological action.
In a study conducted in 16 male volunteers, anastrozole did not alter the exposure (as measured by C max and AUC) and anticoagulant activity (as measured by prothrombin time, activated partial thromboplastin time, and thrombin time) of both R-and S-warfarin.
Cytochrome P450 Based on in vitro and in vivo results, it is unlikely that co-administration of Arimidex 1 mg will affect other drugs as a result of inhibition of cytochrome P450.
Arimidex (anastrozole) is a type of anti-cancer medication called an aromatase inhibitor, used for the adjuvant or initial treatment of breast cancer in post-menopausal women. Arimidex works by blocking aromatase enzyme, which is involved in estrogen production in the body, which leads to decreased tumor size or delayed progression of tumor growth in some women. Common side effects of Arimidex include hot flashes, pain, arthritis, headache, increased blood pressure, depression, nausea, vomiting, bone pain, weakened bones, sleeplessness, and rash. Arimidex is not recommended for pregnant mothers under any circumstances. Arimidex may cause fetal harm and terminate pregnancy. It is unknown if Arimidex enters breast milk. Arimidex should not be administered to breastfeeding mothers to avoid any harm to the newborn.
Multimedia: Slideshows, Images & Quizzes
Breast Cancer Quiz: Symptoms & Signs
This Breast Cancer Quiz features signs, symptoms, facts, causes, common forms, terms, risk factors, statistics, and more. ...
Breast Cancer Diagnosis and Treatment
Learn about breast cancer causes, symptoms, tests, recovery, and prevention. Discover the types of treatments such as surgery and...
10 Things Young Women Should Know About Breast Cancer
Is breast cancer genetic? Should I get tested for the BRCA gene? What every young women should know about breast cancer. Discover...
Breast Cancer: Where It Can Spread
When breast cancer spreads, or metastasizes, it often goes to these five places: the lymph nodes, bones, liver, lungs, and brain....
Related Disease Conditions
Second Source article from Government
Breast Cancer in Men
Second Source WebMD Medical Reference
Breast cancer is an invasive tumor that develops in the mammary gland. Breast cancer is detected via mammograms, breast self-examination (BSE), biopsy, and specialized testing on breast cancer tissue. Treatment of breast cancer may involve surgery, radiation, hormone therapy, chemotherapy, and targeted therapy. Breast cancer risk may be lowered by managing controllable risk factors.
Breast Cancer Prevention
Lifestyle changes, a healthy antioxidant-rich diet, exercise, and weight reduction can help reduce a woman's risk of developing breast cancer. It's important to be aware of how risk factors such as family history, lifestyle factors, breast conditions, radiation therapy, and hormonal factors may influence your chances of developing breast cancer. Mammography and breast self-examinations are crucial steps in breast cancer prevention.
Breast Cancer Questions to Ask the Doctor
A diagnosis of breast cancer can be overwhelming, so it's important to write down all your questions before meeting with your doctor.
Breast Cancer and Coping With Stress
Being diagnosed with breast cancer is stressful. Learning relaxation techniques, exercising, eating well, getting adequate sleep, receiving psychotherapy, and maintaining a positive attitude can help you cope. Creating documents, such as an advance directive, living will, and durable power of attorney will outline your wishes in the event that you are no longer able to make decisions regarding your care.
Breast Cancer and Lymphedema
Lymphedema is a common chronic, debilitating condition in which excess fluid called lymph collects in tissues and causes swelling in them. It is common after a mastectomy, lumpectomy or breast cancer surgery and radiation therapy.
Breast Cancer During Pregnancy
Breast cancer occurs in about 1 in every 1,000 pregnant women. Treatment of breast cancer during pregnancy involves surgery, but it is very difficult to protect the baby from the dangerous effects of radiation and chemotherapy. It can be an agonizing to decide whether or not to undergo breast cancer treatment while one is pregnant.
Breast Cancer Recurrence
Breast cancer most often recurs within the first three to five years after the initial treatment. Changes in the look, feel, or appearance of the breast may indicate breast cancer recurrence. Factors related to recurrence include tumor size, tumor grade, hormone receptor status, lymph node involvement, and oncogene expression. Treatment for recurrent breast cancer depends on the initial treatment.
Breast Cancer Clinical Trials
Breast cancer clinical trials are research programs designed to evaluate new medical treatments, drugs, or devices for the treatment of breast cancer. Clinical trials are designed to test the safety and efficacy of new treatments as well as assess potential side effects. Clinical trials also compare new treatment to existing treatments to determine if it's any better. There are many important questions to ask your doctor before taking part in a breast cancer clinical trial.
Breast Cancer in Young Women
About 5% of cases of breast cancer occur in women under the age of 40 years old. Some risk factors for breast cancer in young women include a personal history of breast cancer or breast disease, family history of breast cancer, prior radiation therapy, and the presence of BRCA1/BRCA2 gene mutations. Breast self-exams, clinical breast exams, and screening mammograms may help detect breast cancer. Treatment may include surgery, chemotherapy, radiation, and hormone therapy.
Inflammatory Breast Cancer
Inflammatory breast cancer is an accelerated form of breast cancer that is not usually detected by mammogram or ultrasound. Symptoms of inflammatory breast cancer include pain in the breast, skin change in the breast area, bruise on the breast,sudden swelling of the breast, nipple retraction or discharge, and swelling of the lymph nodes.
Male Breast Cancer
Male breast cancer accounts for 1% of all breast cancers, and most cases are found in men between the ages of 60 and 70. A man's risk of developing breast cancer is one in 1,000. Signs and symptoms include a firm mass located below the nipple and skin changes around the nipple, including puckering, redness or scaling, retraction and ulceration of the nipple. Treatment depends upon staging and the health of the patient.
Estimating Breast Cancer Risk: Questions and Answers
As breast cancer is the most diagnosed non-skin cancer in American women, it is important to know your breast cancer risk. Risk factors include age, age at menarche, age at first live birth, history of breast abnormalities, breast biopsies, race, and history or breast cancer among first-degree relatives.
Breast Cancer Treatment by Stage
Treatment of breast cancer depends upon the stage of the cancer at the time of diagnosis. Some of the various treatments include: hormone therapy, radiation therapy, surgery, chemotherapy, HER2-targeted therapy, neoadjuvant therapy, and adjuvant therapy.
Genetic Testing: Families With Breast Cancer
Breast cancer can be a killer and the decision to get tested to see if a patient is prone to the disease should be discussed with a doctor -- particularly if the woman has a history of breast cancer in her family. Genetic testing can only tell so much about breast cancer risk, however.
Triple-Negative Breast Cancer
Triple-negative breast cancer is more common in Hispanic and African-American women. Signs and symptoms include a lump in the armpit or breast, nipple discharge and inversion, and changes in the breast's skin. Treatment may incorporate surgery, chemotherapy, and radiation therapy.
Breast Cancer Facts
Breast cancer is the most common non-skin cancer of American women, but it can also occur in men. Every year in the U.S., there are over 266,000 new diagnoses of breast cancer. A woman has a risk of one in eight for developing breast cancer at some point during her lifetime.
Breast Cancer Symptoms and Signs
In most cases, there are no early warning signs of breast cancer. Breast cancer may not produce any early symptoms, and in many cases, it is first discovered on screening mammography. The most common sign of breast cancer is a new lump or mass in the breast.
Breast Cancer Treatment
Breast cancer treatments depend upon the type of breast cancer that is present as well as the stage (extent of spread) of the tumor. Treatment for early breast cancer typically involves surgery to remove the tumor. After surgery, medical professionals may administer radiation therapy, chemotherapy, or targeted therapy.
HER2-Positive Breast Cancer
In about 10%-20% of breast cancers, the cancer cells test positive for HER2, sometimes referred to as the HER2/neu protein. HER2 is a growth-promoting protein located on the surface of some cancer cells. HER2-positive breast cancers tend to grow more rapidly and spread more aggressively than breast cancers that are HER2-negative. Doctors do not know what specifically causes some breast cancers to express this protein while others do not.
What Is the BRCA Gene?
BRCA genes (BRCA 1 and 2, when normal, repair damaged DNA) are among the genetic mutations linked to breast cancer, ovarian cancer, and other cancers when mutated. Every woman with a BRCA mutation is at high risk for breast cancer, irrespective of whether she has a family history of breast cancer or not. By age 80, a woman with a BRCA mutation has about an 80% chance of developing breast cancer. BRCA1 and BRCA2 gene mutations also increase the risk of ovarian cancer, by 54% and 23%, respectively.
Breast Cancer Stages
Breast cancer staging is the determination of the extent and spread of the cancer. An individual's health care team uses stages to summarize the extent of the cancer in a standardized way that is recognized by all health care providers. They use this staging to determine the treatment most appropriate for the type of cancer. Cancer staging helps to determine the prognosis, or outlook, of a cancer, including rates of recurrence and survival rates.
Treatment & Diagnosis
- Breast Cancer Husband
- Breast Cancer Treatment Update
- Breast Cancer: A Feisty Women's Discussion
- Breast Cancer, Taking Control: Self-Advocacy 101
- Breast Cancer: The Male View on Survival and Support
- Breast Cancer: Mother-daughter relationships
- Breast Cancer
- Breast Cancer: Early Diagnosis and Prevention
- Breast Cancer: Early Stage Treatments
- Breast Cancer: Clinical Trials - Today's Cutting Edge
- Breast Cancer, Metastatic: Treatment Goals and Therapy Options -- Harold J. Burstein, MD
- Breast Cancer
- Inflammatory Breast Cancer
- Breast Cancer FAQs
- Stress and Aggressive Breast Cancer: Cause or Effect?
- Breast Cancer Risk - Reduced With Exercise
- Herceptin Metastatic Breast Cancer Treatment
- Breastfeeding -- Protection from Breast Cancer?
- Hormone Therapy in Survivors of Breast Cancer
- Breast Cancer: Types of Breast Cancer
- Elizabeth Edwards has Breast Cancer Alert
- Exercise Improves Breast Cancer Survival
- Advanced Breast Cancer in Young Women Increasing
- Angelina Jolie's Mastectomy
- Does Positive Additude Affect Breast Cancer?
- How Common and Dangerous Is Male Breast Cancer?
- How Many Breast Cancer Deaths Are there Each Year?
- Where Can Breast Cancer Spread To?
- Why Is Breast Cancer More Common in Females than Males?
- How Much Breast Cancer is Genetic?
- How Long Can Breast Cancer Patients Live?
- Who Does Breast Cancer Affect?
- How Does Breast Cancer Form?
- How Many Breast Cancer Stages Are There?
- Facts on Breast Cancer Causes, Risk Factors, and Types
- Breast Cancer Symptoms and Signs
- Breast Cancer Detection
- Breast Cancer Treatment
- Breast Cancer and Kylie Minogue - Audio Podcast
Medications & Supplements
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.